An Open Label, Single Arm Phase 1b Study Of Avelumab Plus Axitinib As First Line Treatment In Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Oct 2018 Planned End Date changed from 6 Aug 2020 to 7 Oct 2019.
- 12 Oct 2018 Planned primary completion date changed from 30 Apr 2020 to 13 Aug 2019.
- 31 Aug 2018 Biomarkers information updated